Systemic Sclerosis Clinical Trial
Official title:
Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study
Verified date | March 2013 |
Source | Karolinska University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: Institutional Review Board |
Study type | Interventional |
The hypothesis is that intensive aerobic and endurance muscle training is safe and
beneficial in patients with systemic sclerosis and concurrent interstitial lung disease.
The purpose of the study is to examine the effect of an eight week intensive aerobic
exercise and muscle endurance training program for patients with systemic sclerosis and
50-100 % of forced vital capacity.
A single subject experimental design with repeated systematic measures during a six week
A-phase (baseline period) and an eight week B-phase (intervention period) was used. Physical
capacity (six minute walk test), aerobic capacity (submaximal treadmill test) and muscle
endurance in shoulder and hip flexion (Functional Index 2) are assessed every other week
throughout the 14 week study. Activity limitation (Health Assessment Questionnaire), quality
of life (Short Form 36), Raynaud, Fatigue and Global Health during the recent week (Visual
Analogue Scales) are assessed at weeks 0, 6, 14. The exercise program includes aerobic
exercise corresponding to 15 on the Borg RPE scale (strenuous) and muscular endurance
training three times/week.
Status | Completed |
Enrollment | 4 |
Est. completion date | April 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - limited or diffuse SSc - age 18-80 years - diagnosis duration > 1 year - unchanged medication since 3 months - 50-100 % of normal vital capacity - exercising < once a week - speak and understand the Swedish language - average or below aerobic capacity according to the submaximal treadmill test (< 27 ml/kg x min for women and < 30 ml/kg x min for men) - < 20 % reduced muscle endurance according to the Functional Index-2 Exclusion Criteria: - Sendoxan treatment for alveolitis - Pulmonal hypertension (PAH) - heart condition contraindicating exercise - < 50 % of normal vital capacity - reduced kidney function - not being able to perform the exercise program |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Sweden | Karolinska Univeristy Hospital, Solna | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska University Hospital |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pain | Pain was rated on a Visual Analogue scale, 0-100 | Assessed at 0, 6 and 14 weeks | Yes |
Other | Raynaud's Phenomenon | Patients rated impact of Raynaud's Phenomenon on a VAS, 0-00 | Assessed at 0,6 and 14 weeks | Yes |
Other | Fatigue | Patients rated fatigue on VAS, 0-100. | Assessed at 0,6 and 14 weeks | Yes |
Other | Disease impact on general well-being | Patients rated impact on well-being on a VAS, 0-100. | Assessed at 0,6, and 14 weeks. | Yes |
Primary | Six minute walking test assessing change in physical capacity compared to baseline. | The six minute walking test assesses physical capacity by recording the walking distance achieved during 6 minutes. The participant is instructed to walk in a self-selected speed, but try to walk as fas a distance as possible. Heart rate, saturation and self-rated central and peripheral exertion is assessed at rest and after 2,4, and 6 minutes. | At 0,2,4,6,8,10,12,14 weeks | No |
Secondary | Submaximal treadmill test. | The Minor treadmill test assessed estimated oxygen uptake in ml/kg x min. The test requires a total of eight minutes where the first four minutes are performed on a horizontal treadmill with the patient walking at a self-elected walking speed. During the following four minutes, the patient continues at the same walking speed on a 5 % incline. Work heart rate, saturation, central and peripheral exertion according to the Borg RPE 6-20 scale were recorded after completion of the test. | Assessed at 0,2,4,6,8,10,12, and 14 weeks | No |
Secondary | Functional Index-2 | Functional Index 2 assessed muscle endurance by recording the number of correct performed repetitions in seven muscle groups; Shoulder flexion, shoulder abduction, neck flexion, hip flexion, knee extension, dorsal- and plantar flexion of the ankle. Maximal number of repetitions varies between 0-60 or 0-120 repetitions. | Assessed at 0,2,4,6,8,10,12 and 14 weeks. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT04300426 -
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
|
Phase 2 | |
Recruiting |
NCT06058091 -
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04356755 -
Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.
|
Phase 2 | |
Suspended |
NCT06210945 -
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05947682 -
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT04303208 -
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT05177380 -
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
|
N/A | |
Recruiting |
NCT02551042 -
CSL Behring Sclero XIII
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT01933334 -
Safety and Tolerability of Pirfenidone in Patients With Systemic SclerosisâRelated Interstitial Lung Disease (SSc-ILD) (LOTUSS)
|
Phase 2 | |
Completed |
NCT01468792 -
Hemodynamic Changes in Connective Tissue Disease
|
N/A | |
Terminated |
NCT00848107 -
Open-Label Study of Oral Treprostinil in Digital Ulcers
|
Phase 2 | |
Completed |
NCT00984932 -
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Not yet recruiting |
NCT06412614 -
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
|
||
Terminated |
NCT00622687 -
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A |